Login to Your Account



Horizon, Transcept File NDAs, Too

Chelsea Therapeutics Moves On NDA for Northera in NOH

By Marie Powers


Thursday, September 29, 2011
After a long and winding road that included two Phase III detours, Chelsea Therapeutics International Ltd. moved forward with a new drug application (NDA) for its lead candidate Northera (droxidopa), an orally active synthetic precursor of norepinephrine, to treat symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure, dopamine beta hydroxylase deficiency and nondiabetic autonomic neuropathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription